1430724-53-0

Basic information

• Product Name: 1-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)-3-(furan-2-ylmethyl)urea
• Synonyms: 1-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)-3-(furan-2-ylmethyl)urea
• CAS NO: 1430724-53-0
• Molecular Weight: 464.486
• Mol File: 1430724-53-0.mol

Chemical Properties

• CAS DataBase Reference: 1-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)-3-(furan-2-ylmethyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)-3-(furan-2-ylmethyl)urea(1430724-53-0)
• EPA Substance Registry System: 1-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)-3-(furan-2-ylmethyl)urea(1430724-53-0)

Safety Data

• Hazardous Substances Data: 1430724-53-0(Hazardous Substances Data)

Upstream product

• 1430724-52-9 N-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430728-09-8 N-(3-(5-bromo-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430729-69-3 N-(3-((2-amino-4-bromophenyl)amino)-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430728-08-7 N-(3-((4-bromo-2-nitrophenyl)amino)-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430728-07-6 N-(3-amino-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430728-06-5 N-(3-nitro-5-(1H-pyrazol-1-yl)phenyl)acetamide 
• 1430728-11-2 3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrazol-1-yl)aniline 
• 71189-15-6 2-(isocyanatomethyl)furan 
• 231287-74-4 N-(3-bromo-5-nitrophenyl)acetamide 
• 55215-57-1 1-amino-3-bromo-5-nitrobenzene 
• 99-65-0 meta-dinitrobenzene 
• 18242-39-2 3,5-dinitrobromobenzene 

Relevant articles and documents

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.